Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market Size, Share, Opportunities, And Trends By Type (Diagnostic Testing, Pharmacological Drugs, Surgical Treatment), And By Geography - Forecasts From 2025 To 2030

Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market Size:

The Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market is expected to grow from USD 5.917 billion in 2025 to USD 8.549 billion in 2030, at a CAGR of 7.64%.

This research study examines the idiopathic pulmonary fibrosis diagnostic and treatment market based on various segments: type and geography. First, a brief overview of the market details key driving factors and challenges. Next, Porter's five forces model analyzes the idiopathic pulmonary fibrosis diagnostic and treatment market comprehensively. This is followed by industry value chain analysis which determines the companies which are part of the different processes and contributing to various sectors.

The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the idiopathic pulmonary fibrosis diagnostic and treatment market. Moreover, the research study analyzes the overall regulatory framework of the idiopathic pulmonary fibrosis diagnostic and treatment market, offering stakeholders a better understanding of the key factors influencing the overall market environment.

Idiopathic pulmonary fibrosis diagnostic and treatment market is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape and details strategies of key market players and also plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.

The scope and coverage of the idiopathic pulmonary fibrosis diagnostic and treatment market report is as below:

• Idiopathic pulmonary fibrosis diagnostic and treatment market data tables and charts
• Market outlook with sections on drivers, restraints, Porter’s and industry value chain analysis
• Market assessment by type into diagnostic testing, pharmacological drugs, and surgical treatment.
• A 360° view of the demand for idiopathic pulmonary fibrosis diagnostic and treatment market solutions/services across different geographies (North America, South America, Europe, Middle East and Africa, and Asia Pacific) with further breakdown for key countries within those regions.

Different segments covered under the idiopathic pulmonary fibrosis diagnostic and treatment market report are as below:

• By Type
  • Diagnostic Testing
  • Pharmacological Drugs
  • Surgical Treatment
• By Drug Type
  • Pirfenidone
  • Nintedanib
  • Others
• By Route of Administration
  • Oral
  • Parenteral
• BY End-Use
  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK 

5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE 

5.1. Introduction

5.2. Diagnostic Testing

5.3. Pharmacological Drugs

5.4. Surgical Treatment

6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE 

6.1. Introduction

6.2. Pirfenidone

6.3. Nintedanib

6.4. Others

7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION

7.1. Introduction

7.2. Oral

7.3. Parenteral

8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE 

8.1. Introduction

8.2. Hospitals and Clinics

8.3. Ambulatory Surgical Centers

8.4. Others

9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. United States

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil 

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. United Kingdom

9.4.2. Germany

9.4.3. France

9.4.4. Spain

9.4.5. Others

9.5. Middle East & Africa

9.5.1. Saudi Arabia

9.5.2. Israel

9.5.3. UAE

9.5.4. Others

9.6. Asia Pacific

9.6.1. Japan

9.6.2. China

9.6.3. India

9.6.4. South Korea

9.6.5. Indonesia

9.6.6. Thailand

9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Roche Holding AG

11.2. Boehringer Ingelheim

11.3. AdAlta

11.4. FibroGen, Inc.

11.5. United Therapeutics

11.6. Galecto Biotech

12. APPENDIX

12.1. Currency 

12.2. Assumptions

12.3. Base and Forecast Years Timeline

12.4. Key benefits for the stakeholders

12.5. Research Methodology 

12.6. Abbreviations 

Roche Holding AG

Boehringer Ingelheim

AdAlta

FibroGen, Inc.

United Therapeutics

Galecto Biotech